Education
About Us
Working with TipRanks
Follow Us
Soleno Therapeutics Inc (SLNO)
NASDAQ:SLNO
SLNO Stock Chart & Stats
Day’s Range― - ―
52-Week Range$36.61 - $74.00
Previous CloseN/A
Volume118.06K
Average Volume (3M)1.56M
Market Cap
$3.31B
Enterprise Value$1.74B
Total Cash (Recent Filing)$1.27M
Total Debt (Recent Filing)$13.99M
Price to Earnings (P/E)―
Beta-0.92
Next Earnings
May 13, 2025EPS Estimate
-0.89Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-4.26
Shares Outstanding45,857,292
10 Day Avg. Volume3,493,812
30 Day Avg. Volume1,564,661
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-23.50
P/FCF Ratio0.00
Enterprise Value/Market Cap0.52
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-10.00
Forecast
1Y Price Target
$99.13Price Target Upside37.38% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
---
Bulls Say, Bears Say
Bulls Say
Market PositionVYKAT XR represents the first pharmacologic option for hyperphagia in Prader-Willi syndrome, addressing a significant unmet need in the community.
Pricing StrategyThe disclosed annualized pricing of $466,200 represents moderate upside to the original pricing assumption.
Regulatory ApprovalThe FDA approval of VYKAT XR for treating hyperphagia in Prader-Willi syndrome is a significant milestone for Soleno Therapeutics.
Bears Say
Financial PerformanceSoleno ended 2024 with $318.6M in cash, cash equivalents, short- and long-term investments; these resources are expected to be sufficient to fund operations through the DCCR launch and possibly cash flow breakeven.
Launch TimelineAssuming DCCR approval in late March 2025, Soleno is expected to start generating revenue in mid-2025.
Regulatory ChallengesThe FDA accorded Priority Review to this NDA, which originally conferred a Prescription Drug User Fee Act (PDUFA) action date of December 27, 2024, and extended the PDUFA date late last year.
---
Ownership Overview
17.69% Insiders
12.95% Mutual Funds
0.09% Other Institutional Investors
60.84% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
SLNO FAQ
What was Soleno Therapeutics Inc’s price range in the past 12 months?
Soleno Therapeutics Inc lowest stock price was $36.61 and its highest was $74.00 in the past 12 months.
What is Soleno Therapeutics Inc’s market cap?
Soleno Therapeutics Inc’s market cap is $3.31B.
When is Soleno Therapeutics Inc’s upcoming earnings report date?
Soleno Therapeutics Inc’s upcoming earnings report date is May 13, 2025 which is in 39 days.
How were Soleno Therapeutics Inc’s earnings last quarter?
Soleno Therapeutics Inc released its earnings results on Feb 27, 2025. The company reported -$1.27 earnings per share for the quarter, missing the consensus estimate of -$0.974 by -$0.296.
Is Soleno Therapeutics Inc overvalued?
According to Wall Street analysts Soleno Therapeutics Inc’s price is currently Undervalued.
Does Soleno Therapeutics Inc pay dividends?
Soleno Therapeutics Inc does not currently pay dividends.
What is Soleno Therapeutics Inc’s EPS estimate?
Soleno Therapeutics Inc’s EPS estimate is -0.89.
How many shares outstanding does Soleno Therapeutics Inc have?
Soleno Therapeutics Inc has 45,857,292 shares outstanding.
What happened to Soleno Therapeutics Inc’s price movement after its last earnings report?
Soleno Therapeutics Inc reported an EPS of -$1.27 in its last earnings report, missing expectations of -$0.974. Following the earnings report the stock price went up 8.513%.
Which hedge fund is a major shareholder of Soleno Therapeutics Inc?
Currently, no hedge funds are holding shares in SLNO
---
Soleno Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$99.13 (37.38% Upside)
$99.13 (37.38% Upside)
Blogger Sentiment
Neutral
SLNO Sentiment 50%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Decreased
By 1.7M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $174.8M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 3.8%
Last 30 Days ▲ 24.1%
Last 30 Days ▲ 24.1%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
72.79%
12-Months-Change
Fundamentals
Return on Equity
-87.35%
Trailing 12-Months
Asset Growth
83.17%
Trailing 12-Months
Company Description
Soleno Therapeutics Inc
Soleno Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead candidate is Diazoxide Choline Controlled-Release, a once-daily oral tablet for the treatment of Prader-Willi Syndrome, which is being evaluated in an ongoing Phase III clinical development program. The company was formerly known as Capnia, Inc. and changed its name to Soleno Therapeutics, Inc. in May 2017. Soleno Therapeutics, Inc. was incorporated in 1999 and is based in Redwood City, California.
---
SLNO Stock 12 Month Forecast
Average Price Target
$99.13
▲(37.38% Upside)
Technical Analysis
Crispr Therapeutics AG
―
Rhythm Pharmaceuticals
―
Akero Therapeutics
―
Immunovant
―
Sotera Health
―
Best Analysts Covering SLNO
1 Year
1 Year Success Rate
8/8 ratings generated profit
1 Year Average Return
+235.16%
initiated a buy rating 10 days ago
Copying Kristen Kluska's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +235.16% per trade.
---